Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Worldwide Offices
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      ACTO LAUNCHES CXZONE: THE FIRST AI-SIMULATED ROLEPLAY SOLUTION BUILT EXCLUSIVELY FOR PHARMA FIELD PROFESSIONALS AND INTEGRATED WITH VEEVA PROMOMATS AND MEDCOMMS


      News provided by

      ACTO Technologies, Inc.

      24 Jul, 2025, 12:30 GMT

      Share this article

      Share this article


      A Specialized Practice Environment to Sharpen Clinical Fluency, Master Product Messaging, and Drive Continuous Improvement Through a Gamified Experience

      TORONTO and NEW YORK, July 24, 2025 /PRNewswire/ -- ACTO, a leader in AI-first commercial learning, enablement, and customer engagement solutions for life sciences and a Veeva Product Partner and member of the Veeva AI Partner Program, today announced the launch of CxZone, the first and only AI-simulated roleplay solution exclusively designed for pharmaceutical field professionals and integrated with Veeva PromoMats and MedComms. Built to improve customer experience (CX), CxZone helps field teams master clinical conversations in a fast, flexible, and feedback-rich environment tailored to the unique nuances of the industry.

      Continue Reading
      This image opens in the lightbox
      ACTO: AI-Powered Intelligent Field Excellence for Life Sciences--ensuring field reps are competent, confident, and credible in face-to-face HCP interactions.
      This image opens in the lightbox
      Announcing CxZone, the first and only AI-simulated roleplay solution exclusively designed for pharmaceutical field professionals and integrated with Veeva PromoMats and MedComms. CxZone helps field teams master clinical conversations in a fast, flexible, and feedback-rich environment tailored to the unique nuances of the industry. CxZone gives field reps and MSLs judgment-free, on-demand practice with instant feedback aligned to a company’s unique sales process and coaching models.

      CxZone gives field reps and MSLs judgment-free, on-demand practice with instant feedback aligned to a company's unique sales process and coaching models. Unlike generic AI roleplay tools, CxZone goes beyond basic sales skill development, focusing on what matters most in HCP conversations—clinical fluency and product messaging. Practice scenarios in CxZone can be built around content auto-synced with Veeva PromoMats and MedComms, ensuring field professionals always practice with current, approved materials. This drives usage of promotional materials, scientific articles, clinical study reports, and other resources that enhance the HCP experience.

      "We're thrilled about CxZone as it mirrors the dynamic nature of our field teams' conversations with Eye Care Professionals," said Sheryl Bisson, Senior Manager, Training & Development at Johnson & Johnson Vision. "It will enhance our reps' confidence and clinical skills, allowing them to excel in every interaction. This could truly be a game-changer."

      CxZone is built on ACTO's proprietary Empathetic AI engine, which makes the AI-simulated HCP interaction realistic and personal. In CxZone, field professionals can model their practice avatar to match the type of HCP, therapeutic area, and mood that matches their target HCP.

      CxZone also incorporates insight about your field professionals, such as their role, product set, and competency strengths and weaknesses, so HCP avatar questions and responses are hyper-relevant to elevate rep performance.

      As part of its upcoming roadmap, ACTO will soon introduce My HCP, a powerful new CxZone capability that brings a deeper level of personalization to simulations. By integrating unique HCP data and insights from Veeva Vault CRM—such as prescribing behavior, hospital affiliations, patient volume estimates, and speaker program participation—My HCP will allow field users to practice with realistic digital twins of their actual customers. This personalization is further enhanced by enabling reps and MSLs to capture the unique nuances of each HCP relationship. Combined with behavioral data like content engagement, sampling history, and call notes from Veeva Vault CRM, My HCP will simulate next-best conversations with unprecedented context and realism.

      CxZone's key differentiators include:

      • True-to-life HCP avatars that match the profile of your reps' customers, convey the typical time pressure of interactions, and challenge reps with realistic clinical questions and responses

      • Tailored AI simulations that align with a company's unique training methodology, sales process, and coaching models

      • Specialized practice zones focused on clinical fluency and product messaging, powered by the latest MLR-approved content from Veeva PromoMats and MedComms

      • Gamified experience that automates instant measurement scores, practice streaks, and individual performance trends to drive engagement

      • Built for compliance — SOC 2 Type II certified, ensuring data is secure and controlled and validated to comply with FDA 21 CFR Part 11 to meet the required regulatory standards for security, integrity, and reliability

      "In life sciences, the success of a new therapy hinges on how effectively reps, MSLs and clinical specialists engage the HCP, especially in complex therapeutic areas," said Parth Khanna, CEO of ACTO. "With CxZone, we set out to reimagine roleplay from the ground up, addressing real-world industry challenges like limited HCP access, inconsistent coaching, and field resistance to traditional methods. The result is the industry's only gamified, AI-driven roleplay solution integrated with Veeva. With CxZone, it's not just about practicing a pitch; it's about building clinical fluency, anticipating real-world objections, and speaking the language of medicine with clarity and confidence. HCP interactions are more valuable, and trust is built. CxZone is truly a breakthrough moment for customer experience in life sciences."

      CxZone is now available to life sciences companies looking to improve the customer experience and elevate their field force performance in the moments that matter most.

      For more information or to request a demo, visit www.acto.com/CxZone.

      Visit www.acto.com, or follow ACTO on LinkedIn for the latest company announcements and news.

      About ACTO

      ACTO is an Intelligent Field Excellence (IFE) platform built for life sciences that unifies human intelligence with empathetic AI to help Sales, Medical, Market Access, and Marketing teams improve customer engagement and brand performance. With ACTO, biopharma companies can ensure field professionals are always competent, confident, and credible in face-to-face HCP interactions, while providing senior leaders and frontline managers with the insight they need to drive continuous field force effectiveness. As a validated platform compliant with FDA 21 CFR Part 11 and SOC 2 Type II certified, ACTO is the trusted partner for intelligent field excellence in the life sciences industry.

      Photo - https://mma.prnewswire.com/media/2737392/ACTO_Technologies__Inc__ACTO_LAUNCHES_CXZONE__THE_FIRST_AI_SIMUL.jpg
      Photo - https://mma.prnewswire.com/media/2737364/ACTO_Technologies__Inc__ACTO_LAUNCHES_CXZONE__THE_FIRST_AI_SIMUL.jpg

      Modal title

      Also from this source

      ACTO Named a Luminary in Everest Group's "Innovation Watch: Agentic AI in Life Sciences Commercial 2026"

      ACTO Named a Luminary in Everest Group's "Innovation Watch: Agentic AI in Life Sciences Commercial 2026"

      ACTO, uniting human intelligence with empathetic AI in Life Sciences, today announced that it has been named a Luminary in Everest Group's Innovation ...

      ACTO Named Among Everest Group's Top 50™ Pharmaceutical Technology Providers for 2026

      ACTO Named Among Everest Group's Top 50™ Pharmaceutical Technology Providers for 2026

      ACTO, uniting human intelligence with empathetic AI in Life Sciences, today announced its inclusion in Everest Group's Top 50™ Pharmaceutical...

      More Releases From This Source

      Explore

      STEM (Science, Tech, Engineering, Math)

      STEM (Science, Tech, Engineering, Math)

      Pharmaceuticals

      Pharmaceuticals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Artificial Intelligence

      Artificial Intelligence

      News Releases in Similar Topics

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.